PubMed · 2000 · 84 citations · 23 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapySolid Tumor PharmacotherapyChemotherapy Toxicity ManagementResponse AssessmentToxicity ManagementTreatment EffectivenessGemcitabine-based TherapyHodgkin Lymphoma TherapyNon-hodgkin Lymphoma TherapyPhase Ii InvestigationPyrimidine AnaloguesRefractory Solid Tumors
BACKGROUND AND OBJECTIVES: To assess the efficacy and the toxic profile of gemcitabine, a novel pyrimidine antimetabolite active against several solid tumors, we carried out a study in heavily pretreated Hodgkin's disease (HD) patients. DESIGN AND METHODS: From May 1997 to January 1999, 14 pretreated patients (10 relapsed and 4 refractory to previous treatments) were enrolled in a phase II trial and treated with gemcitabine. The drug was given on days 1, 8 and 15 of a 28-day schedule at a dose of 1,200 mg/m2 intravenously for a total of 6 cycles. RESULTS: Two (14%) patients achieved complete remission (CR) and 4 (29%) had partial responses (PR), giving an overall response rate of 43%. In the relapsed subset there was an overall response rate of 50% with 2 CR and 3 PR. Among the refractory patients there was only 1 PR (25%). Both patients who had relapsed after autologous bone marrow transplant achieved a response (1 CR and 1 PR). No major toxic effects were recorded. INTERPRETATION AND CONCLUSIONS: These data suggest that gemcitabine is an effective drug with a low toxicity profile in patients with heavily pretreated HD. Further trials using gemcitabine in combination with other conventional drugs are needed.
23
Twenty years of MOPP therapy for Hodgkin's disease.
Dan L. Longo, Robert C. Young, Margaret Wesley et al. · Journal of Clinical Oncology · 1986 · 439 citations
Gemcitabine: preclinical pharmacology and mechanisms of action.
William Plunkett, Peng Huang, C. E. Searcy et al. · PubMed · 1996 · 395 citations